Gem Aromatics Ltd (GEMAROMA)
🎯 Key Takeaways
- Gem Aromatics Ltd is in a strategic turnaround phase, transitioning from a mature chemical producer to a higher-margin specialty ingredients player with global expansion ambitions. Despite revenue growth, the company is currently in a phase of heavy investment and margin compression, with profitability expected to improve only as new product lines scale and utilization improves at its Dahej facility.
- Revenue declined 10.5% QoQ to ₹99 in Q1FY27.
- ⚠️ Persistent margin pressure from raw material volatility and product mix shifts, despite management's claims of normalization.
- Market Cap
- ₹820
- P/B Ratio
- 1.82
- ROE
- -3.2%
- ROCE
- -0.2%
- Debt/Equity
- 0.33
- Promoter
- 57.5%
📖 The Story
Gem Aromatics Ltd is in a strategic turnaround phase, transitioning from a mature chemical producer to a higher-margin specialty ingredients player with global expansion ambitions. Despite revenue growth, the company is currently in a phase of heavy investment and margin compression, with profitability expected to improve only as new product lines scale and utilization improves at its Dahej facility.
📰 What's Happening
In Q1FY27, consolidated revenue rose 12.8% YoY to ₹98.9 crores, driven by growth in mint and clove segments, but gross margin collapsed to 16.7% from 29.5% YoY due to raw material cost pressures and Dahej capex-related depreciation. Management highlighted progress in cooling agents, Safranal, and phenol derivatives, with revenue expected from Q3FY27 onward. A new Brazil subsidiary is being established to expand Latin American distribution, and capex of ~₹270 crores is underway to scale Krystal Ingredients. The board approved the financial results and inventory valuation change to FIFO, applied prospectively. Shareholding shows stable promoter holding (~57%), with FII and DII interest modest but persistent.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 88 | 90 | 79 | 110 | 99 |
| Operating Profit | 13 | -0 | -2 | 7 | -6 |
| OPM % | 14.9% | -0.0% | -2.1% | 6.1% | -5.9% |
| Net Profit | 8 | -3 | -5 | 1 | -8 |
| EPS | ₹2.24 | ₹-0.58 | ₹-1.04 | ₹0.19 | ₹-1.56 |
The company's financial trajectory reflects a clear shift from profitability to investment-driven losses, with consolidated PAT turning negative at ₹-7.9 crores in Q1FY27 (-198.6% YoY), despite revenue growth. This is directly attributable to ₹9.1 crores of depreciation from Dahej capex and margin erosion from lower-margin product mix. Earlier quarters showed volatility — including a strong ₹8 profit in Jun 2025 — but the current trend is defined by rising capex and declining margins, signaling a deliberate but painful transition toward higher-value products.
🔮 Management Outlook & What's Next
Management expects revenue contributions from new high-margin products — cooling agents, Safranal, and phenol derivatives — to begin in Q3FY27 and scale meaningfully by FY28, supporting margin recovery. The launch of a Brazil subsidiary and expansion of Krystal Ingredients' Dahej facility are central to this strategy. Management acknowledges near-term profitability pressure but cites normalized raw material conditions post-Madagascar floods and customer approvals as enablers of a gradual ramp-up in higher-value sales.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 |
| Reserves | 275 | 239 | 439 | 445 |
| Borrowings | 225 | 126 | 150 | 144 |
| Total Liabilities | 535 | 417 | 642 | 658 |
| Fixed Assets | 54 | 49 | 253 | 217 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 535 | 417 | 642 | 658 |
The balance sheet shows a stable but modest equity base of ₹10 crores with reserves growing to ₹445 crores, indicating retained earnings accumulation over time. Borrowings have declined slightly to ₹144 crores from ₹225 crores YoY, suggesting prudent deleveraging despite active capex. Total assets rose to ₹658 crores, supported by investments in Dahej expansion. The capital structure remains conservative, with room for further investment without significant financial strain, though profitability is not yet self-sustaining.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +30 |
| Investing | -101 |
| Financing | +78 |
| Net Cash Flow | +6 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 55.1% | 55.1% | 57.0% | 57.5% |
| FII | 2.0% | 0.8% | 1.1% | 0.8% |
| DII | 6.6% | 4.6% | 4.8% | 4.8% |
| Public | 14.7% | 17.0% | 14.7% | 15.6% |
| # Shareholders | 76,626 | 69,768 | 62,512 | 60,190 |
Promoter holding remains stable near 57%, with no signs of dilution or sale. FII ownership is low but steady (~0.75%), while DII interest has held firm at ~4.8%. Public shareholding has fluctuated slightly but remains material at ~15%. The shareholder base is stable, with no abrupt exits or aggressive accumulation. The increase in shareholder count from 62,512 to 69,768 suggests growing retail interest, possibly ahead of new product visibility.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.50 L Cr | 56.5 | 33.4% | — | 0.01 |
| SRF | 72,171 | 33.4 | 15.6% | — | 0.36 |
| LINDEINDIA | 52,799 | 96.6 | 17.5% | — | 0.00 |
| FLUOROCHEM | 48,774 | 79.7 | 9.6% | — | 0.34 |
| NAVINFLUOR | 42,232 | 53.4 | 22.2% | — | 0.31 |
| GODREJIND | 35,513 | 30.2 | 9.2% | — | 4.57 |
| HSCL | 33,663 | 41.8 | 20.7% | — | 0.16 |
| AETHER | 23,029 | 97.7 | 13.8% | — | 0.08 |
| DEEPAKNTR | 20,783 | 26.5 | 15.3% | — | 0.26 |
| CASTROLIND | 19,792 | 18.6 | 76.2% | — | 0.00 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent margin pressure from raw material volatility and product mix shifts, despite management's claims of normalization. 2. Execution risk in scaling new product lines and achieving target utilization at Dahej, which is critical for margin recovery. 3. High dependency on a few key products and customer segments, with new verticals still unproven at scale. 4. Capex intensity may strain cash flows if revenue ramp-up is delayed, despite healthy OCF of ₹30 crores in Mar 2026.
📋 Recent Filings
- Insider Trading2026-09-24Gem Aromatics Ltd announced that its trading window closes on October 1, 2026, for designated persons and relatives until 48 hours after the unaudited…
- 🔴 Corporate Action2026-09-22Gem Aromatics announced on September 22, 2026, that its board approved converting an existing inter-company loan to Krystal Ingredients Private Limite…
- 🔴 annual report2026-09-22Gem Aromatics Ltd reported a ₹721 crore market cap as of March 31, 2026, with revenue driven by 65% mint derivatives, 23% clove derivatives, 11% other…
- Announcement2026-08-20Gem Aromatics reported Q1 FY27 standalone revenue of **₹83 crores** (up from **₹76 crores** YoY) and consolidated revenue of **₹99 crores** (up from *…
- 🔴 Financial Results2026-08-13Gem Aromatics reported standalone revenue of ₹83.0 crores for Q1FY27, up 8.6% YoY from ₹76.4 crores in Q1FY26, but down 26.1% QoQ from ₹112.2 crores i…
- 🟡 Board Meeting2026-08-13The board approved unaudited standalone and consolidated financial results for Q1 June 2026, showing revenue of **₹871.43 crores** standalone and **₹9…
- 🔴 Financial Results2026-08-13Gem Aromatics reported consolidated revenue of **₹98.9 crores** for Q1FY27, up **12.8% YoY**, driven by growth in mint and clove segments despite seas…
- Announcement2026-08-11Gem Aromatics Limited announced an investor and analyst conference call scheduled for August 14, 2026 at 4:00 PM IST to discuss unaudited Q1 FY27 fina…
- 🟡 Board Meeting2026-07-28Gem Aromatics Limited announced its 29th Annual General Meeting scheduled for August 19, 2026, via video conference, where shareholders will vote on a…
- 🟡 concall transcript2026-06-30Gem Aromatics reported Q1 FY27 consolidated revenue of INR99 crores with 16.7% gross margins and a INR7.9 crore loss driven by Dahej capex depreciatio…
🧠 Analyst's Read
Gem Aromatics is executing a capital-intensive transformation toward specialty chemicals with long-term margin potential, but near-term results will remain volatile. Investors should monitor the rollout of new products from Q3FY27 onward and any acceleration in revenue contribution from the Brazil subsidiary as early indicators of progress.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GEMAROMA files new disclosures
Track GEMAROMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GEMAROMA — FreeFree account · 2 AI queries/day